Effects of Combination Treatment of Alpha 1-Adrenergic Receptor Antagonists on Voiding Dysfunction: Study on Target Organs in Overactive Bladder Rats
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Overactive bladder (OAB) causes urinary urgency, usually accompanied by frequency and nocturia. Alpha 1-adrenergic receptor (α1-AR) antagonists are known to improve lower urinary tract symptoms associated with OAB. The α1-AR antagonists constitute a variety of drugs according to the receptor subtype affinity. This study investigated the efficacy of tamsulosin, naftopidil, and a combination of the two on OAB rats. Methods: The OAB rat model was induced by an intraperitoneal injection of cyclophosphamide for 14 days. The experimental groups were divided into 5 groups: control group, OAB-induction group, OAB-induction and tamsulosin monotherapy group, OAB-induction and naftopidil monotherapy group, and OAB-induction and tamsulosin-naftopidil combination therapy group. For the drug-treated groups, each drug was administrated for 14 days after the OAB induction. Cystometry for urodynamic evaluation and immunohistochemical stain for c-Fos and nerve growth factor (NGF) expressions in the central micturition centers were performed. Results: Increased contraction pressure and time with enhanced c-Fos and NGF expressions in the central micturition centers were found in the OAB rats. Tamsulosin suppressed contraction pressure and time while inhibiting c-Fos and NGF expressions. Naftopidil showed no significant effect and combination therapy showed less of an effect on contraction pressure and time. Naftopidil and combination therapy exerted no significant effect on the c-Fos and NGF expressions. Conclusions: Tamsulosin showed the most prominent efficacy for the treatment of OAB compared to the naftopidil and combination. The combination of tamsulosin with naftopidil showed no synergistic effects on OAB; however, further studies of addon therapy might provide opportunities to find a new modality.
Abstract
Purpose: Overactive bladder (OAB) causes urinary urgency, usually accompanied by frequency and nocturia. Alpha 1-adrenergic receptor (α1-AR) antagonists are known to improve lower urinary tract symptoms associated with OAB. The α1-AR antagonists constitute a variety of drugs according to the receptor subtype affinity. This study investigated the efficacy of tamsulosin, naftopidil, and a combination of the two on OAB rats. Methods: The OAB rat model was induced by an intraperitoneal injection of cyclophosphamide for 14 days. The experimental groups were divided into 5 groups: control group, OAB-induction group, OAB-induction and tamsulosin monotherapy group, OAB-induction and naftopidil monotherapy group, and OAB-induction and tamsulosin-naftopidil combination therapy group. For the drug-treated groups, each drug was administrated for 14 days after the OAB induction. Cystometry for urodynamic evaluation and immunohistochemical stain for c-Fos and nerve growth factor (NGF) expressions in the central micturition centers were performed. Results: Increased contraction pressure and time with enhanced c-Fos and NGF expressions in the central micturition centers were found in the OAB rats. Tamsulosin suppressed contraction pressure and time while inhibiting c-Fos and NGF expressions. Naftopidil showed no significant effect and combination therapy showed less of an effect on contraction pressure and time. Naftopidil and combination therapy exerted no significant effect on the c-Fos and NGF expressions. Conclusions: Tamsulosin showed the most prominent efficacy for the treatment of OAB compared to the naftopidil and combination. The combination of tamsulosin with naftopidil showed no synergistic effects on OAB; however, further studies of addon therapy might provide opportunities to find a new modality.
참고문헌 (26)
- Abrams P, "The standardisation of terminology in lower urinary tract function:report from the standardisation sub-committee of the International Continence Society", Urology, 61, pp.37~49 (2003)
- Andersson KE, "Pharmacotherapy of the overactive bladder", Discov Med, 8, pp.118~124 (2009)
- Chu FM, "Pathophysiology of overactive bladder", Am J Med, 119(3 Suppl 1), pp.3~8 (2006)
- 김성은, "Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder", International Neurourology Journal, 16(1), pp.13~22 (2012), 대한배뇨장애요실금학회
- Schwinn DA, "α1-adrenoceptor subtypes and lower urinary tract symptoms", Int J Urol, 15, pp.193~199 (2008)
- Lepor H, "Alpha 1 adrenoceptor subtypes in the human prostate", J Urol, 149, pp.640~642 (1993)
- 서진희, "Treadmill exercise prevents GABAergic neuronal loss with suppression of neuronal activation in the pilocarpine-induced epileptic rats", Journal of exercise rehabilitation, 11(2), pp.80~86 (2015), 한국운동재활학회[DOI]
- Fowler CJ, "Integrated control of lower urinary tract--clinical perspective", Br J Pharmacol, 147(Suppl 2), pp.14~24 (2006)
- Yokoyama O, "Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving alpha1-blocker treatment: a multi-centre, prospective, randomised study", World J Urol, 33, pp.659~667 (2015)
- Takei R, "Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors", Jpn J Pharmacol, 79, pp.447~454 (1999)
- Griwan MS, "Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia", Urol Ann, 6, pp.181~186 (2014)
- Athanasopoulos A, "Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study", J Urol, 169, pp.2253~2256 (2003)
- Jeong MS, "The role of spinal and peripheral α1-and α2-adrenoceptors on bladder activity induced by bladder distension in anaesthetized rat", BJU Int, 85, pp.925~931 (2000)
- Nishino Y, "Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study", BJU Int, 97, pp.747~751 (2006)
- Holstege G, "Micturition and the soul", J Comp Neurol, 493, pp.15~20 (2005)
- Robinson D, "A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome", BJU Int, 100, pp.840~845 (2007)
- Vignes JR, "Sacral neuromodulation in lower urinary tract dysfunction", Adv Tech Stand Neurosurg, 30, pp.177~224 (2005)
- Kitta T, "Brain-bladder control network: the unsolved 21st century urological mystery", Int J Urol, 22, pp.342~348 (2015)
- Kruse MN, "Pontine control of the urinary bladder and external urethral sphincter in the rat", Brain Res, 532, pp.182~190 (1990)
- Rickey LM, "Estrogen-sensitive projections from the medial preoptic area to the dorsal pontine tegmentum, including Barrington’s nucleus, in the rat", Neurourol Urodyn, 27, pp.440~445 (2008)
- Mitsui T, "Chemical bladder irritation provokes c-fos expression in the midbrain periaqueductal gray matter of the rat", Brain Res, 967, pp.81~88 (2003)
- Griffiths D, "Bladder control, urgency, and urge incontinence:evidence from functional brain imaging", Neurourol Urodyn, 27, pp.466~474 (2008)
- Nour S, "Cerebral activation during micturition in normal men", Brain, 123, pp.781~789 (2000)
- Roehrborn CG, "Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies", BJU Int, 92, pp.257~261 (2003)
- Lepor H, "Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group", Urology, 51, pp.901~906 (1998)
- Hara N, "The role of naftopidil in the management of benign prostatic hyperplasia", Ther Adv Urol, 5, pp.111~119 (2013)